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3-Iodothyronamine (T1AM) is an endogenous high-affinity ligand of the trace amine-
associated receptor 1 (TAAR1), detected in mammals in many organs, including the
brain. Recent evidence indicates that pharmacological TAAR1 activation may offer
a novel therapeutic option for the treatment of a wide range of neuropsychiatric
and metabolic disorders. To assess potential neuroprotection by TAAR1 agonists, in
the present work, we initially investigated whether T1AM and its corresponding 3-
methylbiaryl-methane analog SG-2 can improve learning and memory when systemically
administered to mice at submicromolar doses, and whether these effects are modified
under conditions of MAO inhibition by clorgyline. Our results revealed that when i.p.
injected to mice, both T1AM and SG-2 produced memory-enhancing and hyperalgesic
effects, while increasing ERK1/2 phosphorylation and expression of transcription factor
c-fos. Notably, both compounds appeared to rely on the action of ubiquitous enzymes
MAO to produce the corresponding oxidative metabolites that were then able to activate
the histaminergic system. Since autophagy is key for neuronal plasticity, in a second
line of experiments we explored whether T1AM and synthetic TAAR1 agonists SG1
and SG2 were able to induce autophagy in human glioblastoma cell lines (U-87MG).
After treatment of U-87MG cells with 1 µM T1AM, SG-1, SG-2 transmission electron
microscopy (TEM) and immunofluorescence (IF) showed a significant time-dependent
increase of autophagy vacuoles and microtubule-associated protein 1 light chain
3 (LC3). Consistently, Western blot analysis revealed a significant increase of the
LC3II/LC3I ratio, with T1AM and SG-1 being the most effective agents. A decreased
level of the p62 protein was also observed after treatment with T1AM and SG-1, which
confirms the efficacy of these compounds as autophagy inducers in U-87MG cells. In
the process to dissect which pathway induces ATG, the effects of these compounds
were evaluated on the PI3K-AKT-mTOR pathway. We found that 1 µM T1AM,
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SG-1 and SG-2 decreased pAKT/AKT ratio at 0.5 and 4 h after treatment, suggesting
that autophagy is induced by inhibiting mTOR phosphorylation by PI3K-AKT-mTOR
pathway. In conclusion, our study shows that T1AM and thyronamine-like derivatives
SG-1 and SG-2 might represent valuable tools to therapeutically intervene with
neurological disorders.
Keywords: thyronamines, trace amine-associated receptors, learning, memory, neuroprotection, autophagy,
PI3K-AKT-mTOR
INTRODUCTION
Trace amine-associated receptors (TAARs) represent a novel
class of G protein coupled receptors (GPCRs) identified in
2001 by two independent groups (Borowsky et al., 2001;
Bunzow et al., 2001). At first they were suggested to bind low
abundance neurotransmitters termed “trace amines” (TAs),
namely β-phenylethylamine, p-tyramine, tryptamine, and
octopamine (Lindemann et al., 2005). The best-described
member of the TAARs family is TAAR1 (Borowsky et al., 2001;
Lindemann et al., 2005), which is relatively conserved among
different animal species. TAAR1 is homologous to the dopamine,
noradrenaline, and serotonin receptors and expressed in multiple
organs including the brain, heart, liver, kidney, pancreas, and
spleen. Although, its molecular signaling mechanisms have not
yet been fully elucidated, TAAR1 couples to a Gαs protein and,
upon stimulation, increases intracellular generation of cAMP
via adenylyl cyclase activation, thus stimulating the inwardly
rectifying K+ channels (Borowsky et al., 2001; Bunzow et al.,
2001; Miller et al., 2005; Xie et al., 2007; Bradaia et al., 2009).
TAAR1 signaling has been shown to promote PKA and PKC
phosphorylation, resulting in the upregulation of CREB and
NFAT transcription factors in activated lymphocytes (Panas et al.,
2012), suggesting a possible role for TAAR1 in the modulation
of the immune function. Besides Gαs-protein, TAAR1 signaling
also involves G-protein independent pathways, such as the
β-arrestin2-dependent pathway engaging the protein kinase B
(AKT)/glycogen synthase kinase 3 (GSK3β) signaling cascade, a
key player in dopaminergic neurotransmission (Harmeier et al.,
2015).
During the past two decades, trace amine-associated receptor
1 (TAAR1) has been the focus of extensive research, particularly
because, in addition to TAs as principal binding ligands, it is also
activated by a number of endogenous and exogenous molecules,
including catecholamines, amphetamine and amphetamine-like
compounds, ergot derivatives and several adrenergic ligands
(Bunzow et al., 2001; Pei et al., 2016), as well as certain recently
discovered thyroid hormones derivatives, named thyronamines
(TAMs) (Scanlan et al., 2004; Hart et al., 2006). Since 2004
two specific TAMs (Figure 1), namely 3-iodothyronamine
(3-T1AM or T1AM) and thyronamine (T0AM), proposed to
derive from thyroid hormone, TH, through deiodination and
decarboxylation, were identified in various organs, including
brain, liver, pancreas, and in human plasma, with T1AM being
the most abundant (Scanlan et al., 2004; Scanlan, 2009; Saba et al.,
2010; Zucchi et al., 2014; Hoefig et al., 2016; Chiellini et al., 2017).
T1AM was considered as a novel chemical messenger since it
FIGURE 1 | Chemical structures of thyronamines (T0AM, T1AM), their
thyroacetic acid catabolites (TA0, TA1) and the corresponding synthetic
analogs (SG1, SG2, SG5, and SG6)
was found to produce functional effects being a powerful and
rapid activator of the rat and mouse TAAR1 (Scanlan et al., 2004;
Scanlan, 2009).
Notably, the T1AM skeleton includes a β-phenylethylamine
structure, a feature that may confer T1AM the ability of
recognizing multiple cell targets including other G protein-
coupled receptors, such as adrenergic receptors ADRα2A and
ADRβ2 (Dinter et al., 2015a,b), muscarinic receptors (Laurino
et al., 2016) and TAAR type 5 (TAAR5) (Dinter et al., 2015c)
as well as ion channels, particularly the thermosensitive transient
receptor potential melastatin 8 channel (TRPM8) (Khajavi et al.,
2015). On the other hand, ligands of the dopamine, serotonin,
histamine, or noradrenaline receptors also activate TAAR1-
mediated signaling, although with a low potency (Borowsky
et al., 2001; Bunzow et al., 2001; Alexander et al., 2013a). The
co-existence of the aforementioned ligands in mammals brings
into question the occurrence of cross-interrelations at the level
of ligand–receptors interactions, which may impact at multiple
levels orchestrated signaling events and physiological responses.
Pharmacological administration of T1AM affects reversibly
and dose-dependently reversible effects on body temperature,
cardiac function, energy metabolism, and neurological functions
(Zucchi et al., 2014). Moreover, intracerebral administration of
T1AM at doses close to its physiological levels (µg/kg) improves
learning ability, reverses amnesia, modulates sleep and feeding,
and reduces pain threshold to hot stimuli in mice (Manni et al.,
2013; Laurino et al., 2017). Notably, these effects are prevented by
pre-treatment with the monoamine-oxidase (MAO)-A inhibitor
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clorgyline (Alexander et al., 2013b), suggesting that the oxidative
deamination of T1AM into 3-iodothyroacetic acid (TA1)
(Figure 1) might contribute, at least in part, to the acute effects
of T1AM in vivo. Recent findings provided compelling evidence
that TA1 is generated in vivo by T1AM and that it plays a
significant role in T1AM-induced behavioral effects (Laurino
et al., 2015a,b). These observations strongly suggest the potential
of T1AM and its metabolites/analogs for the treatment of
endocrine and neurodegenerative disorders, including memory
dysfunction (Manni et al., 2013; Laurino et al., 2015a). Recently,
specific TAAR1 antagonists were used to acquire preliminary
evidence that at least some electrophysiological effects of T1AM
in the entorhinal cortex are mediated by TAAR1 (Accorroni and
Zucchi, 2016).
Collectively, these findings indicated that T1AM might
represent a valuable tool to investigate the physiological role
and pharmacological potentials of TAAR1, as well as a good
starting point to advance development of new targets for
potential therapeutic interventions in a wide array of pathological
processes, including metabolic, endocrine, and neurological
disorders. In this context, with the aim to ameliorate the
number of selective TAAR1 agonists, Chiellini et al. (2015,
2016), recently developed a novel class of halogen free
biaryl-methane thyronamine analogs, namely SG compounds,
synthetically more accessible than traditional thyronamines.
Following a multidisciplinary approach, they identified two
compounds, namely SG-1 and SG-2 (Figure 1), that appeared
to be equipotent to endogenous thyronamines (i.e., T0AM and
T1AM, respectively), providing additional tools for studying the
physiological roles of TAAR1 receptor using in vitro and/or
in vivo models.
To assess the therapeutic potential of thyronamine derivatives
for neuroprotection, in the present paper, we initially investigated
whether T1AM and its corresponding 3-methylbiaryl-methane
analog SG-2 can improve learning and memory when
systemically administered to mice at submicromolar doses,
and whether these effects are modified under conditions of MAO
inhibition by clorgyline. In addition, several lines of evidence
indicate that autophagy (ATG), the process by which cells digest
their own cytoplasmic constituents within lysosomes, is key for
neuronal plasticity (Levine and Kroemer, 2008; Son et al., 2012).
The dynamic process of autophagy, defined as autophagy flux, is
orchestrated by several autophagy-related proteins, among which
the yeast ATG-8 mammalian homolog microtubule-associated
protein 1 light chain 3 (LC3) (mammalian homolog of yeast
Atg8) is commonly used as an important biomarker of the
autophagic process (Kabeya et al., 2000; Tanida, 2011; Sarkar,
2013). In addition to LC3, other autophagy substrates can be
exploited for monitoring autophagy flux (Mizushima et al.,
2010). Among these, p62, also known as SQSTM1/sequestosome
1, is perhaps the most studied. Indeed, p62 binds directly to
LC3 and is selectively incorporated into autophagosomes, and
subsequently degraded by autophagy (Bjørkøy et al., 2005),
leading to an inverse correlation between total p62 cellular
expression levels and autophagic activity.
Impairments of the autophagic process are associated with
several neurodegenerative disorders, such as Alzheimer’s disease
(AD), Parkinson’s disease, and Huntington’s disease, where a
deficiency in the elimination of defective or aggregated proteins
may lead to cellular stress, failure and death. As such, the
induction of autophagy may be exploited as a strategy to assist
neurons clearing abnormal protein aggregates and thus survive
(Nixon, 2013). The kinase mammalian target of rapamycin
(mTOR) is a major modulator of autophagy (Crino, 2016; Garza-
Lombó and Gonsebatt, 2016). PI3K/AKT pathway modulates
mTOR activity which is altered in neurodegenerative diseases,
including Alzheimer’s and Parkinson’s disease (Heras-Sandoval
et al., 2014). In particular, in dementia a marked up-regulation
of mTOR, which relates with disease severity, has been described
in humans (Tramutola et al., 2015). Hence, the ideal cell line for
in vitro studies should feature a similar mTOR up-regulation.
This is the case for U-87MG cells as we demonstrated in
previous papers (Arcella et al., 2013; Ferrucci et al., 2017;
Ryskalin et al., 2017) in which mTOR up-regulation leads
to ATG suppression. Incidentally, the suppression of ATG in
degenerative dementia is considered to be responsible also for
altered glia-related inflammation. Thus, the U-87MG cell line
is also well suited to investigate the involvement of glial cells
since they represent an immortalized glioblastoma derived glial
cells where mTOR upregulation is prominent. The ability to
suppress mTOR in this cell line is remarkable due to an aberrant
baseline mTOR overexpression just like in dementia (Wang et al.,
2013).
Therefore, to explore the potential neuroprotective effects of
thyronamines, we also evaluated the ability of T1AM and newly
developed analogs SG-1 and SG-2 to promote autophagy in
U-87MG cells, while investigating the signaling pathway being
involved.
MATERIALS AND METHODS
Chemicals
3-Iodothyronamine was kindly provided by Prof. Thomas
Scanlan (Portland, OR, United States) and was dissolved in 0.5%
DMSO (Veh). SG-1, SG-2, and SG-6 analogs were synthesized by
our group according a procedure previously described (Chiellini
et al., 2015) and were dissolved in 0.5% DMSO (Veh). Clorgyline
and pyrilamine were supplied by Sigma–Aldrich, St. Louis, MO,
United States.
Animals
Experiments and animal care used procedures were in
accordance with the National Institutes of Health Guide for
the Care and Use of Laboratory Animals (NIH Publications
No. 80-23, revised 1996). The experimental protocols were
approved by the Animal Care Committee of the Department of
Pharmacology, University of Florence, in compliance with the
European Convention for the Protection of Vertebrate Animals
used for Experimental and Other Scientific Purposes (ETS no.
123) and the European Communities Council Directive of 24
November 1986 (86/609/EEC). The authors further attest that all
efforts were made to minimize the number of animals used and
their suffering.
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Male mice (CD1 strain; 20–30 g) from Envigo (Udine, Italy)
were used. Five mice were housed per cage and the cages
were placed in the experimental room 24 h before the test for
adaptation. Animals were kept at 23 ± 1◦C with a 12 h light–
dark cycle (light on at 07:00 h) and were fed a standard laboratory
diet with water ad libitum. All studies involving animals are
reported in accordance with the ARRIVE guidelines for reporting
experiments involving animals (Kilkenny et al., 2010; McGrath
et al., 2010).
Behavioral Tests
The Passive Avoidance Paradigm: The Light–Dark
Box
The passive avoidance paradigm test using the light–dark box
apparatus was carried out using the step-through method by
Jarvik and Kopp (1967), and following a procedure already
described in previous studies (Manni et al., 2013; Musilli et al.,
2014). The test was carried out by comparing the effect of vehicle
(Veh; 0.5% DMSO) or test compound (i.e., T1AM or SG-2; 1.32,
4, and 11 µg·kg−1; n= 20 for each treatment) injected i.p. to the
mice prior to the training session of the test.
Determination of Mice Pain Threshold to Thermal
Stimulus Using the Hot Plate
Mice were injected i.p. with test compound (i.e., T1AM or SG-2;
1.32, 4, and 11 µg·kg−1) or vehicle (n = 20 for each group) and,
after 15 min, they were placed on the hot plate set at 51.5◦C. The
time taken to observe a licking, flinching or jumping response
was measured. The cut-off time was set at 45 s to minimize skin
damage.
In another set of experiments, additional mice were pretreated
with i.p. clorgyline (2.5 mg·kg−1) or with the histamine H1
receptor antagonist pyrilamine (10 mg·kg−1) and after 30 min
they received the test compound (i.e., T1AM or SG-2; 1.32, 4, and
4µg·kg−1) or saline (i.p.). Measurements were performed 15 min
after i.p. injections.
Identification of T1AM or SG-2 Activated Signaling in
Mouse Brain and Dorsal Root Ganglion (DRG)
Mouse brain and DRG tissue preparations
Mice were removed from the cage and injected i.p. with vehicle
or test compound (i.e., T1AM or SG-2; 1.32, 4, and 11 µg·kg−1).
Animals were sacrificed at two different time points, 15 min
or 5 h, after test compound or vehicle administration. The
brain was excised and the forebrain was split into two
sections: frontal cortex and diencephalon. The hippocampus,
hypothalamus/thalamus were then quickly removed, and all
tissues were flash-frozen in liquid nitrogen and stored at −80◦C
until use. In another set of experiments, mice were sacrificed
15 min after i.p. injection with vehicle or test compound (i.e.,
T1AM or SG-2; 1.32, 4, and 11 µg·kg−1). DRG were freshly
isolated using a previously described procedure (Vellani et al.,
2004). Briefly, 20–30 ganglia were isolated from the full length
of the spinal column following removal of the spinal cord, and
stored in 0.5% SDS at−80◦C until use.
Brain and DRG samples were homogenized in
homogenization buffer containing (in mM): 50 Tris-HCl
at pH 7.5, 150 NaCl, 1 EDTA, 5 sodium pyrophosphate,
10 β-glycerophosphate, 1 Na3VO4, 0.2 PMSF, 25 µg·mL−1
leupeptin, 10 µg·mL−1 aprotinin and 0.1% SDS. To remove cell
debris, homogenates were centrifuged at 1000 × g for 10 min at
4◦C and the supernatants (brain lysates) used for Western blot
analysis.
Western blot analysis
Proteins (20 µg) isolated from selected brain regions and
DRG homogenates were separated on 4–20% SDS-PAGE and
transferred into PVDF membranes (60 min at 398 mA)
using standard procedures. Membranes were blocked in PBST
(PBS containing 0.1% Tween) containing 5% non-fat dry
milk for 60 min. Blots were incubated overnight at 4◦C
with specific antibody against ERK1/2 phosphorylated on
Thr202/Tyr204 (pERK1/2, Cell Signaling Technology) or c-fos
(Sigma–Aldrich S.r.l, Milan, Italy). Primary antibodies were
diluted in PTBS containing 3% albumin. After being washed
with PBST, the membranes were incubated with polyclonal
goat anti-rabbit HRP-conjugated secondary antisera (1:2,000,
diluted in PTBS containing 5% non-fat dry milk) and left
for 1 h at room temperature. Blots were then extensively
washed and developed using an enhanced chemiluminescence
detection system (Pierce Scientific, Rockford, IL, United States).
Exposition and developing time were standardized for all blots.
Densitometric analysis of scanned images was performed on a
Macintosh iMac computer using the public domain NIH Image
program. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH,
Sigma–Aldrich S.r.l., Milan, Italy) or β-actin (Sigma–Aldrich,
S.r.l., Milan, Italy) were used as loading control. Protein
concentration was quantified using Bradford’s method (protein
assay kit, Bio-Rad Laboratories, Segrate, Milan, Italy).
Data represent mean ± SEM of three different experiments.
Results are expressed as arbitrary units (AU), consisting of the
ratio between the expression levels of the protein of interest and
that of the GAPDH.
Induction of Autophagy in Cell Lines
Cell Lines
U-87MG human glioma cell lines from Cell Bank (IRCC
San Martino-IST, Genova) were cultured in standard DMEM-
High Glucose medium (Sigma–Aldrich S.r.l., Milan, Italy)
supplemented with 10% fetal bovine serum (FBS), 1% of MEM
non-essential amino-acid (MEM-NEAA), penicillin (50 IU/mL)
and 100 µg streptomycin (Sigma–Aldrich S.r.l., Milan, Italy).
Cells were kept at 37◦C in a humidified atmosphere with 5% CO2
and the medium was renewed two to three times per week.
For transmission electron microscopy (TEM) and Western
blot (WB) assays, the cells were cultured at a density of 1 × 106
cells/well in a 6-well plate in a final volume of 2 ml/well. For
confocal light microscopy (IF) assay 3 × 104 cells were seeded
on cover- slips in 24-well plates in a final volume of 1 ml/well.
In order to evaluate cytotoxicity (Trypan blue assay) and cell
viability (MTT assay), 1 × 104 cells were seeded in 96-well plate
in a final volume of 400 ml/well. Twenty-four hours after seeding,
the cells were treated with test compounds (T1AM, SG1, and
SG2) at the dose of 1 µM for different exposure times (30’, 4, 8,
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and 24 h). Dilutions of test compounds were obtained by a stock
solution (1 mM in saline containing 10% DMSO).
Trypan Blue (Cytotoxicity Assay)
For trypan blue staining, after incubation with the different drugs
the cells were collected and centrifuged at 800 rpm for 5 min.
The cell pellet was suspended in culture medium and 25 µl of
the cellular suspension were added to a solution containing 1% of
trypan blue (62.5 µl) and PBS (37.5 µl). The cells were incubated
for 5 min at room temperature. Then, a volume of 10 µl of this
solution was counted using a Bürker glass chamber and a light
microscope. Viable and non-viable cells were recorded and the
cell viability was expressed as a percentage of number of viable
cells/number of total cells. The values represent the means of
three independent cell counts.
MTT (Cell Viability Assay)
Cell viability was measured by using 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) reagent (Mosmann,
1983). In brief, after incubation with the different drugs, 10 µL
of MTT reagent (0.5 mg/ml) was added to the medium and the
cells were incubated for 3 h at 37◦C. The resultant insoluble
MTT-formazan dark red crystals were dissolved with 100 µl
of solubilization buffer (10% SDS in 0.01M HCl) and after
incubating for 7 h at 37◦C, absorbance at OD570 nm was
determined with an automated microplate reader (BIO-TEK,
Winooski, VT, United States). The percentage of cell viability was
calculated using the following formula: Cell viability (%) = Cells
number (treated)/Cells number (DMSO control) Å∼ 100.
Transmission Electron Microscopy (TEM)
Glioblastoma U-87MG cells were collected using trypsin and
centrifuged at 1,000 × g for 5 min. After the supernatant was
removed, the pellet was thoroughly rinsed in PBS. Cell pellets
were fixed in 2.0% paraformaldehyde + 0.1% glutaraldehyde in
0.1M PBS (pH 7.4) for 90 min at 4◦C. This procedure is used
to prevent specific TEM artifacts caused by high concentrations
of aldehydes, which could hinder our ability to detect authentic
autophagy-like vacuoles (Fornai et al., 2001). Postfixation was
done in an aqueous solution of 1% OsO4 for 1 h at 4◦C; then
the specimens were dehydrated in ethanol and embedded in
Epoxy-resin. Ultrathin sections (50–70 nm) were cut using a
Leica Ultramicrotome R and contrasted using uranyl acetate
(saturated solution in distilled water) and lead citrate to be
finally observed by using a Jeol JEM SX 100 electron microscope
(Jeol).
For ultrastructural morphometry, non-serial sections were
examined directly by TEM at 5,000× magnification. At least
10 cells per section were identified in each grid and several
grids were examined to achieve a total of at least 30 cells
per experimental group. Autophagy-like vacuoles, identified
as double or multiple membranes (autophagosomes-like)
containing cytoplasmic material and electrondense membranous
structures (Fornai et al., 2007; Lenzi et al., 2012), were counted.
Values were calculated using ImageJ software and expressed
as density of autophagy-like vacuoles (number of autophagy-like
vacuoles per surface unit).
Confocal Microscopy (IF)
U-87MG cells grown overnight on coverslips were washed
twice with phosphate-buffered saline (PBS) and fixed with
methanol at room temperature for 5 min. Retrieval of the
antigen was achieved in 100 µM Tris-HCl, 5% urea at 95◦C
for 10 min. After washing with PBS, cells were permeabilized
with 0.2% Triton X-100 for 10 min at room temperature,
and subsequently blocked in PBST (PBS + 0.1% Tween-
20), supplemented with 1% bovine serum albumin (BSA) and
22.52 mg/ml of glycine, for 30 min. The cells were then incubated
overnight at 4◦C in 1% BSA in PBST containing 1:50 anti-
LC3 antibody (Abcam, Cambridge, United Kingdom). After
extensive PBST washes, cells were incubated for 1 h at room
temperature with a 1:200 dilution of goat anti-rabbit secondary
antibody (Alexa 488, Molecular Probes, Life Technologies) in
1% BSA in PBST. Cells were then washed with PBS, mounted
in Prolong Diamond Antifade Mountant (Molecular Probes,
Life Technologies) and subsequently examined. The analysis
was performed using a Leica TCS SP5 confocal laser-scanning
microscope (Leica Microsystems, Mannheim, Germany) using
a sequential scan procedure. Confocal images were collected
every 400 nm intervals through the z-axis of sections by means
of 20x and 63x oil lenses. Z-stacks of serial optical planes
were analyzed using the Multicolor Package software (Leica
Microsystems). Negative controls were performed, omitting the
primary antibody. Fluorescence intensity was analyzed by using
ImageJ program.
Western Blot Analysis
1 × 106 U-87MG cells were seeded in 6-well plates in a final
volume of 2 ml/well and grown to 80% of confluence with
standard medium (DMEM-High Glucose). Cells were treated
with vehicle (0.1% DMSO) or 1 µM test compounds (T1AM,
SG-1, and SG-2) and incubated at 37◦C for 30 min, 4, 8, and 24 h.
Treated cells were washed twice with PBS and lysed in Tris-
buffered saline buffer-1% Triton-X100; NaCl 150 mM; Tris-HCl
20 mM; EDTA 1 mM; EGTA 1 mM; NaF 20 mM; Na4P2O7
25 mM; Na3VO4 1 mM; PMSF 1 mM; 8 µl/ml protein cocktail
inhibitors (Sigma–Aldrich, Milan, Italy). Proteins (20–30 µg)
were separated on Criterion TGXTM gel (4–20%) and transferred
on Immuno-PVDF membrane (Bio-Rad, Milan, Italy) for
1 h. Blots were incubated for 12 h with diluted primary
antibody [1:1000, LC3A/B; p62; Akt, p-Akt(Ser 473), β-actin, Cell
Signaling] in 5% w/v BSA, 1X TBS and 0.1% Tween R© 20 at 4◦C
under gentle shaking. Then, blots were washed three times for
10 min with 1X TBS, 0.1% Tween R© 20 and incubated for 1 h
with secondary antibody (peroxidase-coupled anti rabbit in 1X
TBS, 0.1% Tween R© 20). After washing three times for 10 min, the
reactive signals were revealed by enhanced ECL Western Blotting
analysis system (Amersham). Band densitometric analysis was
performed using Image Lab Software (Bio-Rad, Milan, Italy).
Statistical Analysis
Data are reported as the mean ± SEM. Statistical analysis
was performed by one-way analysis of variance (ANOVA),
followed by Student–Newman–Keuls multiple comparison post
hoc test. The threshold of statistical significance was set at
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P < 0.05. Data analysis was performed by Graph-Pad Prism
6.0 statistical program (GraphPad Software Inc., San Diego, CA,
United States).
RESULTS
T1AM and SG-2 Increase Memory
Retention
3-Iodothyronamine is known to induce pro-learning and anti-
amnestic responses when administered i.c.v. at very low doses
(1.32–4 µg·kg−1) to mice, but its effects on memory after
systemic administration are currently unknown. To address this
point, we first evaluated the behavior of CD-1 mice injected i.p.
with T1AM or its 3-methylbiaryl-methane analog SG-2 (1.32, 4,
and 11 µg·kg−1) in the passive avoidance test.
As described in the “Materials and Methods” section, retention
sessions of the passive avoidance test were performed 1 and
24 h after T1AM or SG-2 injection. In the 1 h retention session,
following administration of 4 µg·kg−1 T1AM or SG-2 the latency
to enter the dark compartment was increased, but the difference
versus the control group did not reach the threshold of statistical
significance. However, when either of the two compounds was
administered at the dose of 11 µg·kg−1, a significantly higher
latency to enter the dark compartment was observed at 1 h
(P < 0.05 and P < 0.01 vs. vehicle-treated mice, respectively)
(Figure 2). In the 24 h section both compounds appeared to show
activity at lower doses, even though their effects did not follow a
linear dose–response trend (Figure 2).
T1AM and SG-2 Increase Pain Sensitivity
Since the effect on memory enhancement that was observed
in the passive avoidance test following i.p. injection of T1AM
or SG-2 may involve an analgesic action, we next checked
whether T1AM and SG-2 had any effect on pain threshold. As
shown in Figure 3A, the hot-plate analgesic test revealed that,
when injected i.p. to mice at doses that were effective in the
passive avoidance test (i.e., 4 and 11 µg·kg−1 for T1AM, and
11 µg·kg−1 for SG-2), both compounds significantly reduced the
pain perception threshold to hot insults (P< 0.01 and P< 0.05 vs.
vehicle, respectively). Therefore, neither T1AM nor SG-2 showed
any analgesic effect at the doses applied.
Clorgyline Pretreatment Modulates the
Response to T1AM and SG-2
Oxidative deamination by amine oxidases, followed by
aldehyde oxidation by the widely distributed enzyme aldehyde
dehydrogenase, is known to be the main metabolic pathway
for T1AM (Wood et al., 2009; Saba et al., 2010), leading to
the production of its metabolite 3-iodothyroacetic acid (TA1),
which is not a ligand of TAAR1 (Chiellini et al., 2015). Notably,
many of the neurological effects observed after administering
T1AM i.c.v. were prevented or reduced in animals pre-treated
with clorgyline, a MAO-A inhibitor (Manni et al., 2012, 2013),
suggesting that TA1 may directly or indirectly contribute to the
pharmacology of T1AM.
In addition, the pharmacokinetics of thyronamine-like
synthetic analogs, such as SG-2, has not yet been completely
described. Therefore, it seemed interesting to investigate whether
the hyperalgesic effect observed after systemic administration
of both T1AM and SG-2 was affected by the MAO inhibitor
clorgyline, administered i.p. at the dose of 2.5 mg·kg−1.
In agreement with previous findings, the results of our
pain threshold experiments revealed that the hyperalgesic effect
produced by 11 µg·kg−1 T1AM or SG-2 was lost with clorgyline
pretreatment (Figure 3B). Notably, in control mice i.p. injected
with clorgyline an increased pain sensitivity was observed as
compared to vehicle treated animals. In fact, as shown in
Figure 3B, after treatment with i.p. clorgyline the observed
latencies were generally lower than those observed in vehicle
treated animals.
Effects of H1 Antagonist Pyrilamine on
the Hyperalgesic Response to T1AM and
SG-2
Recent studies showed that i.c.v. injection in mice of equimolar
doses of TA1 reproduced the pro-learning effects induced by
T1AM. Notably, TA1 as well as T1AM pro-learning effects were
modulated by histaminergic antagonists (Musilli et al., 2014;
Laurino et al., 2015b). Therefore, it appeared interesting to
further investigate whether the hyperalgesic effects observed in
mice after 11 µg·kg−1 T1AM or SG-2 i.p. injection are mediated
by the histaminergic system.
As shown in Figure 4, pretreatment with pyrilamine, a type1
histaminergic receptor (H1) antagonist, completely prevented the
hyperalgesic effects of both T1AM and SG-2.
In addition, i.p. injection in mice of equimolar doses of SG-6
(Figure 1), the potential oxidative deamination derivative of
SG-2, which essentially can be considered as the 3-methylbiaryl-
methane analog of TA1, reproduced the hyperalgesic effects
induced by SG-2. In agreement with previous findings on TA1,
SG-6 effects were completely abolished by pretreatment with
pyrilamine (Figure 5).
Notably, pyrilamine per se did not modify the pain perception
to hot insults, which was found to be comparable to that of vehicle
treated animals (Figures 4, 5).
Systemic Administration of T1AM and
SG-2 Activate Central Nervous System
Signaling
Increased ERK1/2 phosphorylation and increased expression
of transcription factor c-fos are commonly associated to
memory acquisition and storage (Giese and Mizuno, 2013;
Minatohara et al., 2015). Indeed, Western blot analysis of
selected brain region lysates (i.e., hypothalamus/thalamus,
hippocampus, and prefrontal cortex) obtained from mice after
treatment with T1AM or SG-2 at doses that demonstrated
to be effective on memory acquisition and retention (i.e.,
4 and 11 mg·kg−1) showed significantly increased pERK
(∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 versus vehicle), and c-fos
(∗P< 0.05 versus vehicle) expression as compared to control mice
(Figures 6, 7).
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FIGURE 2 | SG-2 and T1AM modified learning in mice. Mice were injected i.p. either with SG-2 (1.32, 4, or 11 mg·kg−1), T1AM (1.32, 4, or 11 mg·kg−1) or with
vehicle (Control) and subjected to the passive avoidance test as described in the “Materials and Methods” section. Results are expressed as mean ± SEM; n = 20 in
each group; ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 versus vehicle.
FIGURE 3 | SG-2 and T1AM reduce nociceptive threshold in mice and the
effect is blunted by clorgyline pretreatment. (A) Mice were placed on the hot
plate 15 min after i.p. injection of either SG-2 (1.32, 4, or 11 mg·kg−1), T1AM
(1.32, 4, or 11 mg·kg−1) or vehicle (Control). The latency to respond to the
insult was evaluated as described in the “Materials and Methods” section.
Results are expressed as mean ± SEM; n = 20 in each group; ∗P < 0.05 and
∗∗P < 0.01 versus vehicle. (B) Pain threshold was measured in mice treated
with vehicle (Control), SG-2 or T1AM at their highest dosage (11 mg·kg−1).
Experiments were repeated in mice pretreated with clorgyline (2.5 mg·kg−1,
i.p.) 30 min before receiving the test drugs at the dosage of 11 mg·kg−1, or
vehicle (Control). The nociceptive threshold was determined by the hot plate
test. Results are expressed as mean ± SEM; n = 10 in each group;
∗∗P < 0.01 versus vehicle without clorgyline (Control, left panel).
Spinal extracellular signal-regulated kinases (ERKs) have long
been known as mediators of nociceptive plasticity (Watkins et al.,
1997; Wiertelak et al., 1997), and the measurement of pERK1/2
levels has recently emerged as an extremely reliable marker
for neuronal activation and central sensitization after noxious
stimulation and tissue injury (Gao and Ji, 2009). Therefore,
we investigated the effects of systemic administration of T1AM
or SG-2 on ERK1/2 activation in our experimental model. As
FIGURE 4 | Pretreatment with H1 receptor antagonist pyrilamine abolishes
SG-2 or T1AM-induced hyperalgesia. The nociceptive threshold of mice
pre-treated (s.c.) with the H1 receptor antagonist pyrilamine (10 mg kg−1) was
determined by the hot plate test 15 min after SG-2 or T1AM i.p. injection
(11 µg kg−1) (n = 10 in each group). Results are expressed as means ± SEM;
∗∗P < 0.01 versus vehicle without pyrilamine (Control, left panel).
FIGURE 5 | SG-6 reduces nociceptive threshold in mice and the effect is
blunted by pyrilamine pretreatment. Mice were injected i.p. with SG-6 (1.32, 4,
or 11 µg·kg−1) or with vehicle (Control) and after 15 min their nociceptive
threshold measured by the hot plate test. Experiments were repeated in mice
pre-treated (s.c.) with the H1 receptor antagonist pyrilamine (10 mg kg−1) and
exposed to the hot plate test 15 min after SG-6 i.p. injection (4 or 11 µg
kg−1). Results are expressed as means ± SEM; n = 10 in each group;
∗P < 0.05 and ∗∗P < 0.01 versus vehicle without pyrilamine (Control, left
panel).
depicted in Figure 8, in DRG prepared from mice treated with
4 and 11 µg·kg−1 T1AM or SG-2 a strong activation of ERK1/2
was observed (∗∗P < 0.01 versus vehicle; ∗∗∗P < 0.001 versus
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FIGURE 6 | T1AM and SG-2 induce p-ERK in CD-1 mice brain regions. Fifteen minutes after i.p. injection of either T1AM, SG-2 (4, 11 mg·kg−1) or vehicle (Control),
mice (n = 3 per group) were killed and brain regions separated as described in the “Materials and Methods” section. Immunodetection for p-ERK was carried out on
protein lysates from each region separated on SDS-PAGE gels. A representative experiment for each brain region analyzed is shown. Results are the mean ± SEM
of the densitometry of three different gels. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 versus vehicle.
vehicle). Notably, in the same set of experiments, pretreatment
with pyrilamine followed by administration of T1AM or SG-2
at the highest dosage significantly reduced pERK1/2 detection
(∗∗∗P < 0.001 versus vehicle (Control); ∗∗∗P < 0.001 versus
T1AM 11 µg kg−1 or SG-2 11 µg kg−1) (Figure 8).
Induction of Autophagy in U-87MG Cells
Autophagy is a complex cellular lysosome-mediated process that
eliminates misfolded proteins, protein complexes, or organelles
through lysosomial degradation, and it is required for cellular
homeostasis in cell survival, with neuronal cells representing
one of the most studied systems (Mariño et al., 2011; Radad
et al., 2015). An altered autophagy is described in several models
of neurodegeneration, including Alzheimer’s and Parkinson’s
diseases, as well as after traumatic and ischemic brain injuries
(Galluzzi et al., 2016; Rivero-Rios et al., 2016; Li et al., 2017;
Martinez-Vicente, 2017). Thus, stimulation of autophagy may
lead to a new approach in the treatment of neurological
diseases.
With the aim to explore the role played by T1AM
and recently developed thyronamine-analogs SG-1 and SG-
2 in the autophagy process, we examined the formation of
autophagosomes and the autophagic flux in human glioblastoma
cell lines (U-87MG). U-87MG cells are commonly used as
a model to study neurological diseases, characterized by
an up-regulation of mTOR (molecular target of rapamycin),
an important inhibitor of autophagy (Arcella et al., 2013;
Ryskalin et al., 2017). In our study, U-87MG cells were
treated with 1 µM T1AM, SG-1 and SG-2 for 30 min,
4, 8, and 24 h and the progress of the autophagic flux
was investigated both morphologically, by using TEM and
immunofluorescence microscopy (IF), and biochemically, by
monitoring the expression of autophagy marker proteins, such
as LC3-II (Mizushima et al., 2010) and p62 (Bjørkøy et al., 2005),
by Western blot analysis.
We then proceeded to elucidate which pathway was involved
in ATG modulation by assessing our test compounds on the
PI3K/AKT/mTOR signaling pathway (Song et al., 2005; Jung
et al., 2010).
Ultrastructural Studies
As shown in representative pictures reported in Figure 9A and
in the graphs of Figure 9B the number of ATG-like vacuoles
counted by plain TEM increased in U-87MG cells exposed to
1 µM T1AM, SG-1, or SG-2 for 0.5, 4, 8, and 24 h as compared
to cells in baseline conditions. In detail, the number of vacuoles
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FIGURE 7 | T1AM and SG-2 induce c-fos in CD-1 mice brain regions. Fifteen minutes after i.p. injection of either T1AM, SG-2 (11 mg·kg−1) or vehicle (Control),
mice (n = 3 per group) were killed and brain regions separated as described in the “Materials and Methods” section. (A) Immunodetection for c-fos was carried out
on protein lysates from each region separated on SDS-PAGE gels. A representative experiment is shown. (B) Western blot quantification of c-fos in mice brain
regions after treatment with 11 mg·kg−1 T1AM or SG-2. Results are the mean ± SEM of the densitometry of three different gels. ∗P < 0.05 versus vehicle.
FIGURE 8 | T1AM and SG-2 induce p-ERK1/2 in dorsal root ganglia (DRG) from CD1 mice: the effect of pyrilamine pretreatment. DRG were isolated from mice
randomly treated with saline (Control), T1AM (4, 11 µg kg−1) or SG-2 (4, 11 µg kg−1) with or without being exposed to pretreatment with pyrilamine (10 mg kg−1)
and analyzed for p-ERK1/2 levels by Western blot as described in Methods. (A) p-ERK1/2 in DRG protein lysates. A representative experiment is shown.
(B) Densitometric analysis of p-ERK1/2 levels in DRG from CD1 mice. Results represent mean ± SEM of three different gels. ∗∗P < 0.01 versus vehicle (Control);
∗∗∗P < 0.001 versus vehicle (Control); ∗∗∗P < 0.001 versus T1AM 11 µg kg−1 or SG-2 11 µg kg−1.
significantly increased after treatment with 1 µM T1AM for 4, 8,
and 24 h (∗P< 0.05 compared with baseline conditions), whereas
with 1 µM SG-1 or SG-2 significant effects were observed only
after 8–24 h (∗P < 0.05 compared with baseline conditions), and
24 h treatment (∗P < 0.05 compared with baseline conditions),
respectively (Figure 9B).
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FIGURE 9 | Transmission Electron Microscopy (TEM) shows time-dependent induction of autophagy in U-87MG cells by 1 µM SG-1, SG-2, or T1AM.
(A) Representative pictures of ATG-like vacuoles (arrows) in the cytoplasm in baseline conditions (Control) and after treatment with 1 µM SG-1, SG-2, or T1AM, as
visualized in representative micrographs. (B) The mean number of ATG-like vacuoles per cell was counted and values were reported in graph. Values are given as the
mean ± SEM. Comparisons between groups were made by using one-way ANOVA. ∗P < 0.05 compared with baseline conditions. Scale bars (A,B) = 1 µm.
As shown in Figures 10a,b, IF experiments revealed
significant LC3-puncta formation in U-87MG exposed to 1 µM
SG-1 for 4, 8, and 24 h (∗P < 0.05 and ∗∗P < 0.01 compared
with baseline conditions), whereas SG-2 and T1AM treatments
(1 µM) produced significant effects only at 8 and 24 h of
incubation times (∗P < 0.05 and ∗∗P < 0.01 compared with
baseline conditions).
As shown in Figure 11, Western blot analysis confirmed
autophagy induction in U-87MG cells, revealing a significant
LC3-II up-regulation, after 4 h treatment with all the compounds
examined (∗P < 0.05 versus vehicle treated cells). After 24 h
treatment only T1AM and SG-1 appeared to induce a significant
LC3 II up regulation (∗∗P< 0.01 and ∗∗∗P< 0.001 versus vehicle
treated cells).
Since ultrastructural studies (TEM and IF) and Western blot
analysis have shown that T1AM and SG-1 are more effective than
SG-2 at inducing autophagy in U-87MG cells, we next check the
ability of T1AM and SG-1 to modulate the autophagic flux by
examining their effect on p62 expression in U-87MG cells after
24 h incubation time. Consistently, a significant reduction of p62
expression was observed in U-87MG cells after treatment for 24 h
with 1 µM T1AM and SG-1 (∗∗P < 0.01 versus vehicle treated
cells) (Figure 12), in turn confirming their efficacy as autophagy
inducers.
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FIGURE 10 | Confocal microscopy confirms induction of autophagy in U-87MG cells treated with 1 µM SG-1, SG-2, or T1AM. (a) Representative images of
LC3-expressing cells incubated with 1 µM SG1, SG2 or T1AM 24 h after the treatment. (A) Control cells, (B) SG1-treated cells, (C) SG2-treated cells,
(D) T1AM-treated cells. Scale bars are 25 µm. (E) Higher magnification of one SG1-treated cell expressing LC3 proteins. Scale bar is 10 µm. (b) LC3-expression in
U-87MG cells treated with 1 µM SG-1, SG-2, or T1AM for 30 min, 4, 8, and 24 h. Data are normalized to the appropriate control values. Statistical analysis
performed by student’s t-test. ∗P < 0.05 compared with baseline conditions; ∗∗P < 0.01 compared with baseline conditions.
T1AM, SG-1, and SG-2 Induce Autophagy
via PI3K/AKT/mTOR Pathway
The PI3K/AKT/mTOR signaling pathway is an important
regulator of autophagy, with mTOR playing a key modulatory
role (Song et al., 2005; Jung et al., 2010). Suppression of AKT has
been found to decrease mTOR activity and promote autophagy
(Guertin and Sabatini, 2007). Therefore, we wanted to evaluate
whether the observed induction of autophagy in U-87MG cells
caused by treatment with T1AM, SG-1, and SG-2 is accomplished
via inhibition of the PI3K/Akt/mTOR pathway. To this aim, we
analyzed the phosphorylation status of Akt in U-87MG cells
treated for 30 min and 4 h with 1 µM test compounds. As shown
in Figure 13, T1AM and thyronamine-like analogs SG-1 and
SG-2 significantly reduced the phosphorylation levels of Akt-
Ser 473 in U-87MG cells (∗P < 0.05, ∗∗P < 0.01, versus vehicle
treated cells), suggesting that they may induce autophagy in U-
87MG cells via inhibition of the phosphorylation of mTOR by the
PI3K/AKT/mTOR pathway.
In addition, cellular viability was determined using the MTT
colorimetric assay. No significant alterations of cell viability were
observed in U-87MG cells treated for 24 h with 1 µM TAAR1
agonists (i.e., T1AM, SG-1, and SG-2) as compared to vehicle
(0.1% DMSO) (Figure 14). Absence of cytotoxicity was also
confirmed by Trypan blue dye (data not shown).
DISCUSSION
Trace amine-associated receptor’s family (TAARs) represents a
large class of receptors recently discovered that has become
increasingly popular in Medicinal Chemistry as the focus of
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FIGURE 11 | T1AM, SG-1, or SG-2 increase LC3II/LC3I ratio in U-87MG cells. (A) Representative bands. (B) Western blot quantification of LC3II/LC3I ratio. The
presence of LC3 in autophagosomes and the conversion of LC3 to the lower migrating form LC3-II are used as an indicator of autophagy. Results represent
mean ± SEM of three different gels. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 versus vehicle treated cells (Control).
studies aimed at the discovery of new drugs (Berry et al., 2017).
Among this family of receptors, TAAR1 has gained considerable
interest as the target for developing therapeutic approaches
against a wide range of neurodegenerative and neuropsychiatric
disorders due to its widespread expression in the central nervous
system, its activation by psychoactive drugs, its interrelation
with the dopaminergic and serotoninergic systems, and the
observation that TAAR1 knockout mice display a neurological
phenotype (Miller, 2012; Lam et al., 2015).
Among TAAR1 ligands, the endogenous thyroid hormone
(TH) derivative T1AM was firstly identified by Scanlan in rodent
brain (Scanlan et al., 2004). Later studies demonstrated that
some of its actions partly overlap to the known metabolic and
neurological responses to thyroid hormone (Zucchi et al., 2014;
Accorroni et al., 2017). Therefore, we might speculate that T1AM
might be responsible for some effects traditionally attributed to
thyroid hormone itself, in turn representing a component of
thyroid hormone signaling, and consequently playing significant
physiological and/or pathophysiological roles.
It is well known that thyroid hormone is fundamental
for normal brain development and maintenance of optimal
cognitive ability in different periods of life (Bauer et al.,
2008). In adulthood, thyroid dysfunction leads to neurological
and behavioral abnormalities, including memory impairment.
Central hypothyroidism has been described in patients with AD
(Sampaolo et al., 2005), and the analysis of various experimental
models suggests that the effects on cognition rely on hippocampal
alterations.
Several studies have explored the consequences of
administering T1AM directly into the brain. Recently,
Manni et al. (2012, 2013) reported that intracerebral T1AM
administration at doses close to its physiological levels (µg/kg)
evoked neurological effects improving learning capacity,
FIGURE 12 | Reduced p62 expression in U-87MG cells. (A) Representative
bands. (B) After 24 h, T1AM (1 µM) and SG-1 (1 µM) induced p62
degradation in U-87MG cells. Results represent mean ± SEM of three
different gels. ∗∗P < 0.01 versus vehicle treated cells (Control).
decreasing pain threshold to hot stimuli, enhancing curiosity
and raised plasma glycemia. Notably, the same authors observed
that the effects of T1AM on memory were almost completely
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FIGURE 13 | T1AM, SG-1 and SG-2 reduce the phosphorylation levels of Akt-Ser473 in U-87MG cells. (A) Representative bands and (B) Western blot quantification
of pAkt/Akt ratio in U-87MG cells after treatment with 1 µM T1AM, SG-1, or SG-2 for 30 min and 4 h. Results represent mean ± SEM of three different gels.
∗P < 0.05, ∗∗P < 0.01, versus vehicle treated cells (Control).
FIGURE 14 | Cell viability assay. MTT assay showing U-87MG cells viability
after 24 h treatment with tested compounds. Results are expressed as the
mean ± SEM of 12 biological replicates.
abolished by pretreatment of mice with clorgyline, a MAO
inhibitor that prevents the oxidative deamination of T1AM,
thus reducing the formation of its metabolite 3-iodothyroacetic
acid (TA1). These findings suggest that TA1 might, directly
or indirectly, contribute to the pharmacological effects of
T1AM. Consistently, as recently shown by Musilli et al. (2014),
injection in mice of equimolar doses of TA1 reproduced the
same pro-learning effects induced by T1AM. Modification of
memory, increase of plasma glucose and reduction of pain
threshold were reported following i.c.v. injection of histamine
and of selective histamine receptor agonists in rodents (Nishibori
et al., 1987, 1990; Galeotti et al., 2004). Therefore, the same
authors explored whether the pro-learning effects of TA1 and
T1AM were modulated by histaminergic antagonists (Musilli
et al., 2014; Laurino et al., 2015a,b). Their findings sustained
the hypothesis that T1AM, through biotransformation into
TA1, might be part of the same signaling network linking the
thyroid with histamine, and that TA1 might be considered the
active metabolite of T1AM that is responsible for its memory-
enhancing effects. Dysregulation of the neuronal histaminergic
system is a common phenomenon in different neurodegenerative
disorders, including Parkinson (Anichtchik et al., 2000, 2001)
and Alzheimer diseases (Trillo et al., 2013). Even though a causal
relationship between thyroid, neuronal histaminergic system
dysregulation and the onset of neurodegenerative diseases still
need to be ascertained, maintaining a proper link between
thyroid and histaminergic neurons, through the mediation
of T1AM, might be critical for the preservation of behavioral
circuits, including those involved in memory and learning.
The study we report here demonstrated that T1AM behaves
as a memory enhancer even when injected systemically into
mice at doses comparable to those previously used in central
administration experiments by Manni et al. (2013). At the
dosages active on memory, T1AM also proved to have an
hyperalgesic effect. In addition, our pain threshold experiments
confirmed that TA1, the oxidative metabolite of T1AM, plays a
critical role for T1AM effect. In fact, at our settings, pretreatment
with clorgyline abolished almost completely the effect on pain of
T1AM administered i.p. at the highest dosage (i.e., 11 µg/kg).
The same effect was also confirmed to involve the histaminergic
system, as it disappeared after pretreatment with the histamine
H1-receptor antagonist, pyrilamine.
Recently, the thyronamine-like TAAR1 agonist SG-2, has
been shown to produce a good mimic of T1AM functional
effects in rodents (Chiellini et al., 2015). Consistently, we
carried out parallel experiments to explore the effects of
SG-2 on memory and pain sensitivity. Our results revealed
that SG-2 given i.p. to mice produce memory-enhancing and
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hyperalgesic effects with a potency almost comparable to that of
T1AM. Notably, pretreatment with the histamine H1-receptor
antagonist, pyrilamine also abolished the hyperalgesic effect
elicited by SG-2. Interestingly, even though the presence of
an ethoxyamino side chain should confer SG-2 a greater
resistance to oxidative deamination as compared to T1AM,
pretreatment with clorgyline also dampened SG-2 effects on
pain sensitivity. These findings indicate that SG-2 metabolite(s)
might contribute to its effects. To test this hypothesis, we
explored whether SG-2 potential oxidative metabolite, namely
SG-6, i.p. injected to mice (1.32, 4, and 11 µg/kg) has
the capability of inducing hyperalgesia, and whether this
effect is modulated by histamine. As expected, we found
that SG-6, injected into mice at doses equimolar to those
used for SG-2, reduced the threshold to hot stimuli with
a potency even higher than SG-2. In addition, histamine
appeared to be involved in SG-6 hyperalgesia, since this
effect was also dampened by pretreatment with pyrilamine.
Activation of ERK1/2 is a typical event induced by histamine
receptor activation (Dandekar and Khan, 2011). Accordingly,
increased pERK1/2 levels were found in DRG following
exposure to either T1AM and SG-2. Notably, pretreatment
with H1R antagonist pyrilamine significantly reduced ERK1/2
phosphorylation, supporting the involvement of H1R activation
in the histamine-induced hyper-response to noxious heat
(Nakagawa and Hiura, 2013).
Taken together, our results provide robust evidence that
synthetic thyronamine-like analog SG-2 shares with T1AM the
effectiveness on memory and pain, which seems to involve
a common mechanism of action. Namely, both T1AM and
SG-2 seem to rely on the action of ubiquitous enzymes MAO
to produce the corresponding oxidative metabolites that are
then able to activate the histaminergic system. Although our
knowledge on the pharmacokinetic properties of SG-2 is still
at a preliminary level, the oxidative deamination of SG-2 to
generate the corresponding acid SG-6 has been observed in vitro
using diverse human cancer cell lines, including liver cancer cells
(HepG2) and glioma cells (U-87MG) (unpublished data). Even
though further studies are necessary in order to prove that SG-2
generates SG-6 in vivo, our preliminary data support the notion
that thyronamine-like analogs, such as SG-2, might represent a
new option as “prodrug” candidates for the relief of memory
dysfunction and disturbance of pain perception occurring in
neurodegenerative diseases.
Alzheimer’s disease, accompanied by deterioration in
memory and other cognitive functions, is the most frequent
neurodegenerative disorder. Recent studies indicate that T1AM
counteracts the effects of Aβ on LTP and restores recognition
memory in a mouse model of AD (mhAPP mouse), but the
underlying mechanisms are currently unknown (Accorroni and
Zucchi, 2016). Recent reports have emphasized that disturbed
autophagy is a contributing factor in AD (Nixon and Yang, 2011;
Ghavami et al., 2014). In line with this evidence, we decided
to investigate the ability of T1AM and recently developed
thyronamine-like analogs SG-1 and SG-2 to induce autophagy
in human glioblastoma cell lines (U-87MG). Our ultrastructural
(TEM and IF) and Western blot analyses show that T1AM, as
well as SG-1 and SG-2, were able to increase the LC3-II/I ratio
and decreased SQSTM1(p62), indicating that they could induce
autophagy. Further studies suggested that these effects might
result from the inhibition of the phosphorylation of mTOR
by the PI3K/AKT/mTOR pathway. Promoting cell survival
while activating the autophagic process and the clearance of
abnormal protein aggregates is important to neuroprotection
in the treatment of neurodegenerative diseases. On the other
hand, cytotoxicity or reduction of cell viability were not observed
in U-87MG cells after treatment with our test compounds for
24 h. Ultimately, we provided preliminary evidence that T1AM
and selected thyronamine-like TAAR1 agonists can induce
autophagy. Even though at a low level, TAAR1 is expressed in
U-87MG cells (Hauser and Knapp, 2014). Ongoing experiments
are examining the role of TAAR1 activation in autophagy
induction by pretreatment of U-87MG cells with EPPTB, a
specific TAAR1 antagonist (Bradaia et al., 2009).
CONCLUSION
Our data displayed that T1AM and thyronamine-like TAAR1
agonists SG-1 and SG-2 have neuroprotective properties, which
also involve the induction of autophagy. This novel aspect
requires further investigation. Future in vivo studies will be
carried out to ascertain whether T1AM and TAAR1 agonist
administration in mice may also be able to induce autophagy,
thus providing a more conclusive evidence for the connections
between memory enhancement and induction of autophagy. In
addition, to confirm the positive effects on memory retention,
further experiments will be performed in animal models for
impaired learning processes.
Notably, neurodegenerative diseases are multifactorial
debilitating disorders involving multiple pathways that, in
addition to protein misfolding and aggregation, are characterized
by several metabolic changes, such as mitochondrial dysfunction,
oxidative stress, and phosphorylation impairment, all occurring
concurrently (Nesi et al., 2017). Because of these multifactorial
aspects and complexity, multi-target directed ligand (MTDL)
design and discovery has emerged as a possible strategy for
the treatment of neurodegenerative disorders (Saba Sheikh
et al., 2013). In line with this evidence, we can speculate that
the poly-pharmacological and pharmacokinetic properties
described in good detail for T1AM, and rapidly emerging also
for thyronamine-like analogs, SG-1 and SG-2, may provide a
novel pleiotropic therapeutic approach for the treatment of
neurodegenerative disorders still lacking an effective therapy.
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